GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Brokerages

GeoVax Labs, Inc. (NASDAQ:GOVX) has earned a consensus recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat reports. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $14.20.

GOVX has been the topic of a number of research reports. D. Boral Capital restated a “buy” rating and set a $18.00 target price on shares of GeoVax Labs in a report on Wednesday, December 18th. Alliance Global Partners began coverage on shares of GeoVax Labs in a research report on Monday, November 11th. They set a “buy” rating and a $15.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research note on Friday, November 15th.

GeoVax Labs Stock Performance

Shares of GOVX opened at $2.60 on Tuesday. GeoVax Labs has a one year low of $1.09 and a one year high of $11.18. The company has a 50-day simple moving average of $2.43 and a two-hundred day simple moving average of $2.83.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38. The firm had revenue of $2.79 million during the quarter, compared to analysts’ expectations of $1.84 million. During the same quarter in the previous year, the business earned ($4.80) EPS. As a group, equities research analysts predict that GeoVax Labs will post -4.49 EPS for the current year.

Institutional Trading of GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC purchased a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned about 0.43% of GeoVax Labs as of its most recent SEC filing. 6.09% of the stock is owned by institutional investors.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.